## Adam Platt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4049959/publications.pdf Version: 2024-02-01



Δραγά Βιάττ

#	Article	IF	CITATIONS
1	The commutability of enzyme linked immunosorbent assays for the quantification of serum eosinophil-derived neurotoxin (EDN). Journal of Immunological Methods, 2022, 500, 113181.	0.6	0
2	Rare and Common Variants in <i>KIF15</i> Contribute to Genetic Risk of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 56-69.	2.5	25
3	Eosinophil-derived neurotoxin: A biologically and analytically attractive asthma biomarker. PLoS ONE, 2021, 16, e0246627.	1.1	20
4	Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis. Communications Biology, 2021, 4, 392.	2.0	28
5	Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nature Genetics, 2021, 53, 942-948.	9.4	234
6	Rare variant contribution to human disease in 281,104 UK Biobank exomes. Nature, 2021, 597, 527-532.	13.7	224
7	LTA4H rs2660845 association with montelukast response in early and late-onset asthma. PLoS ONE, 2021, 16, e0257396.	1.1	6
8	Exome-Based Rare-Variant Analyses in CKD. Journal of the American Society of Nephrology: JASN, 2019, 30, 1109-1122.	3.0	40
9	Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. BMC Rheumatology, 2019, 3, 3.	0.6	18
10	Diagnostic Utility of Exome Sequencing for Kidney Disease. New England Journal of Medicine, 2019, 380, 142-151.	13.9	456
11	Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis. Arthritis and Rheumatology, 2018, 70, 1419-1428.	2.9	21
12	Drug development in the era of precision medicine. Nature Reviews Drug Discovery, 2018, 17, 183-196.	21.5	294
13	Accuracy of the HumaSensplus point-of-care uric acid meter using capillary blood obtained by fingertip puncture. Arthritis Research and Therapy, 2018, 20, 78.	1.6	17
14	Early changes in blood-based joint tissue destruction biomarkers are predictive of response to tocilizumab in the LITHE study. Arthritis Research and Therapy, 2016, 18, 13.	1.6	31
15	An analytical comparison between point-of-care uric acid testing meters. Expert Review of Molecular Diagnostics, 2016, 16, 373-382.	1.5	16
16	A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies. BMC Cancer, 2015, 15, 171.	1.1	51
17	Serological Biomarkers of Joint Tissue Turnover Predict Tocilizumab Response at Baseline. Journal of Clinical Rheumatology, 2014, 20, 332-335.	0.5	18
18	Effect of tocilizumab combined with methotrexate on circulating biomarkers of synovium, cartilage, and bone in the LITHE study. Seminars in Arthritis and Rheumatism, 2014, 43, 470-478.	1.6	75

Adam Platt

#	Article	IF	CITATIONS
19	Rheumatoid Arthritis: A Case for Personalized Health Care?. Arthritis Care and Research, 2014, 66, 1273-1280.	1.5	26
20	Genome-wide association analysis implicates the involvement of eight loci with response to to to to ilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics Journal, 2013, 13, 235-241.	0.9	42
21	IL-6 pathway-driven investigation of response to IL-6 receptor inhibition in rheumatoid arthritis. BMJ Open, 2013, 3, e003199.	0.8	47
22	IL-6 Receptor Inhibition Positively Modulates Bone Balance in Rheumatoid Arthritis Patients with an Inadequate Response to Anti-Tumor Necrosis Factor Therapy: Biochemical Marker Analysis of Bone Metabolism in the Tocilizumab RADIATE Study (NCT00106522). Seminars in Arthritis and Rheumatism, 2012, 42, 131-139.	1.6	75
23	Biochemical markers of ongoing joint damage in rheumatoid arthritis - current and future applications, limitations and opportunities. Arthritis Research and Therapy, 2011, 13, 215.	1.6	99
24	Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Pharmacogenetics and Genomics, 2011, 21, 365-374.	0.7	19
25	c-Jun N-Terminal Kinase Primes Endothelial Cells at Atheroprone Sites for Apoptosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2010, 30, 546-553.	1.1	61
26	Evidence for PI-3K-dependent migration of Th17-polarized cells in response to CCR2 and CCR6 agonists. Journal of Leukocyte Biology, 2008, 84, 1202-1212.	1.5	35
27	Synthesis and SAR of aminopyrimidines as novel c-Jun N-terminal kinase (JNK) inhibitors. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 3463-3467.	1.0	53
28	Human Immature Monocyte-Derived Dendritic Cells Express the G Protein-Coupled Receptor GPR105 (KIAA0001, P2Y14) and Increase Intracellular Calcium in Response to its Agonist, Uridine Diphosphoglucose. Journal of Immunology, 2003, 171, 1941-1949.	0.4	92
29	Identification of Both Positive and Negative Domains within the Epidermal Growth Factor Receptor COOH-terminal Region for Signal Transducer and Activator of Transcription (STAT) Activation. Journal of Biological Chemistry, 2002, 277, 30716-30723.	1.6	100
30	The yeast galactose genetic switch is mediated by the formation of a Gal4p–Gal80p–Gal3p complex. EMBO Journal, 1998, 17, 4086-4091.	3.5	166
31	Signaling activation and repression of RNA polymerase II transcription in yeast. BioEssays, 1997, 19, 1001-1010.	1.2	34
32	Genome-wide Enrichment of <i>TERT</i> Rare Variants in IPF Patients of Latino Ancestry. American Journal of Respiratory and Critical Care Medicine, 0, , .	2.5	6